This page shows the latest AMD news and features for those working in and with pharma, biotech and healthcare.
Novartis and smartpatient have launched a new educational app experience for patients with age-related wet macular degeneration (AMD). ... In the future, Novartis and smartpatient also plan to roll the wet AMD section out to further markets. .
That includes its wet AMD drug Lucentis (ranibizumab), which fell 25% to bring in $401m in the quarter.
Beovu (brolucizumab) is the first anti-VEGF treatment to demonstrate superior resolution of retinal fluid compared to Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), according to Novartis. ... aflibercept) squaring off
It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
s Eylea (aflibercept), which together account for the lion’s share of the wet AMD market by value. ... Lucentis was the first VEGF inhibitor to reach the market for wet AMD and grew quickly into a blockbuster product with sales of around $3.7bn last
The green light for Beovu (brolucizumab) is a boost for Novartis as it tries to defend its wet AMD franchise, currently represented by $2bn-plus VEGF inhibitor product Lucentis (ranibizumab) which ... Novartis’ drug was the first VEGF inhibitor to
More from news
Approximately 26 fully matching, plus 76 partially matching documents found.
for advanced dry Age-related Macular Degeneration (AMD).
RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... Effectively the deal is structured as an option, as the phase 2 study in dry AMD will be
treatments for age-related macular degeneration (AMD).
In the EU, where there’s a high prevalence of AMD, Bayer has enjoyed great success with Eylea - growing revenues by 18% in 2017,” says Alice Stevens, analyst, cardiovascular and metabolic ... The company plans to launch the highly anticipated
to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...